Description of Business, Basis of Presentation, and Operating Segment - Additional Information (Details) $ in Millions		12 Months Ended
	Mar. 01, 2019 USD ($) product	Dec. 31, 2019 Segment product
Segment Reporting Information [Line Items]
Number of late stage development drugs | product		3
Number of reportable operating segment | Segment		1
FUSILEV, FOLOTYN, ZEVALIN, MARQIBO, BELEODAQ, EVOMELA, and KHAPZORY | Acrotech Biopharma LLC
Segment Reporting Information [Line Items]
Upfront payment expected to be received	$ 158.8
Consideration held in escrow for six months	4.0
Payment receivable on achievement of regulatory milestones	$ 140.0
Discontinued Operations, Disposed of by Sale | Commercial Product Portfolio
Segment Reporting Information [Line Items]
Number of products | product	7
Payment receivable on achievement of regulatory milestones	$ 40.0
Potential payments based on achievement of sales milestones	$ 100.0